TABLE 1.—LIST OF REGULATIONS—Continued

21 CFR Section	FCC Edition and/or Supplement Currently Referenced	Name of Additive	Current FCC Reference
173.165(d)	3d Ed.	*Candida lipolytica*	Citric acid produced must conform to FCC specifications (under "Citric acid").
173.228(a)	4th Ed.	Ethyl acetate	Meets FCC specifications.
173.280(c)	3d Ed.	Solvent extraction process for citric acid	Meets FCC specifications.
173.310(c)	4th Ed.	Boiler water additives; Sodium carboxymethylcellulose	Contains not less than 95% sodium carboxymethylcellulose on a dry-weight basis, with maximum substitution of 0.9 carboxymethylcellulose groups per anhydroglucose unit, and with a minimum viscosity of 15 centipoises for 2% by weight aqueous determined by the method cited in FCC.
173.310(c)	4th Ed.	Boiler water additives; Sorbitol anhydride esters	Meets FCC specifications.
173.368(c)	4th Ed.	Ozone	Meets FCC specifications.
178.1005(c)	3d Ed.	Hydrogen peroxide solution	Meets FCC specifications.
180.25(b)	3d Ed.	Mannitol	Meets FCC specifications.
180.30(a)	3d Ed.	Brominated vegetable oil	Meets FCC specifications.
180.37(b)	3d Ed.	Saccharin, ammonium saccharin, calcium saccharin, and sodium saccharin	Meets FCC specifications.

The agency has determined under 21 CFR 25.30(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: August 4, 2010.

Catherine L. Copp,

Acting Director, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition.

[FR Doc. 2010–19722 Filed 8–9–10; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Advisory Board, September 7, 2010, 8:30 a.m. to September 8, 2010, 12 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892, which was published in the **Federal Register** on July 22, 2010, 75 FR42758.

This amendment has been processed to change the start and end times of the NCAB meeting. The meeting will now start at 4 p.m. and end at 5:45 p.m. on September 7, 2010. On September 8, 2010, the closed session will be held from 8:30 a.m. to 10 a.m. The open session will start at 10:15 a.m. and end at 5 p.m.

Dated: August 4, 2010.

Anna Snouffer,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–19681 Filed 8–9–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates as Biotherapeutics for the Treatment of HIV and HCV Infections

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the inventions embodied in:

1. U.S. Provisional Patent Application Serial No. 60/576,056, filed on June 1, 2004, entitled "Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use", converted to PCT/US2005/18778, filed May 27, 2005, and entered national stage in U.S. (patent application serial number 11/569,813), Canada (patent application serial number 2,567,728), Australia (patent application serial number 2005250429), Europe (patent application serial number 05804849.7), Japan (patent application serial number 2007–515398), Israel (patent application serial number 179236), New Zealand (patent number 2006/09573), and South Africa (patent application serial number 2006/09573) (HHS reference E–106–2003/0) from Dr. Barry O'Keefe *et al.* (NCI).

2. U.S. Provisional Patent Application Serial No. 60/741.403, filed on